What is D*action?
D*action started out as a 5 year (now on-going) public health project to provide education and research to SOLVE the vitamin D deficiency epidemic, by measuring vitamin D serum levels, collecting health data from participants, and tracking the health effects of getting to levels of 40-60 ng/ml (100-150 nmol/L).
Published by GrassrootsHealth Nutrient Research Institute
Conclusions: In this first controlled study comparing treatments for resistant/intolerant (R/I) pts with CML, asciminib, a first-in-class STAMP inhibitor, demonstrated statistically significant and clinically meaningful superiority in efficacy compared with BOS (primary objective), deeper MR rates, and a favorable safety profile. These results support the use of asciminib as a new treatment option in CML, particularly in R/I pts who received ≥2 prior TKIs.
Chronic myeloid leukemia (CML) is a blood cancer. Unlike other cancers CML treatment is lifelong and many patients experience side effects. For those patients who respond well to treatment and achieve deep molecular remission, quality of life is impacted because of continuous treatment. In this review, we look at emerging clinical trials which aim to investigate which patients can safely stop treatment.
Conclusions: These updated results continue to support 50 mg of dasatinib daily as an effective and safe dose for newly diagnosed early CML-CP.
MyeloidScan – Long COVID in patients with myeloid blood cancers
Have you had COVID 19 infection? We need to find out more about long covid affects people like you – can you help us?
We would like to share with you an opportunity to take part in a study to investigate the impact of COVID-19 infection in people with myeloid blood cancers.
What is the study for?
Asciminib, a first-in-class STAMP inhibitor, may be a new treatment option for patients with chronic myeloid leukaemia in chronic phase (CML-CP) previously treated with 2 or more tyrosine kinase inhibitors.
A British Society for Haematology Guideline on the diagnosis and management of CML
Authors:
Graeme Smith, Jane Apperley, Dragana Milojkovic, Nicholas C. P. Cross, Letizia Foroni, Jenny Byrne, Andy Goringe, Anupama Rao, Jamshid Khorashad, Hugues de Lavallade, Adam J. Mead, Wendy Osborne, Chris Plummer, Gail Jones, Mhairi Copland, behalf of British Society for Haematology
Clinical trials show that tyrosine kinase inhibitor (TKI) treatment can be discontinued in selected patients with chronic myeloid leukaemia (CML). Although updated CML guidelines support such procedure in clinical routine, data on TKI stopping outside clinical trials are limited. In this retrospective study utilising the Swedish CML registry, we examined TKI discontinuation in a population-based setting. Out of 584 patients diagnosed with chronic-phase CML (CML-CP) in 2007–2012, 548 had evaluable information on TKI discontinuation.
Simple Summary
Abstract